The Maximum-Tolerated Dose and Pharmacokinetics of a Novel Chemically Modified Curcumin in Rats

PURPOSE: CMC 2.24, a chemically modified curcumin, was developed as a novel, pleiotropic MMP-inhibitor to treat various inflammatory/collagenolytic diseases including periodontitis. To date, this compound has shown efficacy in vitro, in cell culture, and in vivo (oral administration) in mice, rats a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Heta Dinesh, McClain, Steve A, Lee, Hsi-Ming, Zimmerman, Thomas, Deng, Jie, Johnson, Francis, Gu, Ying, Golub, Lorne M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842656/
https://www.ncbi.nlm.nih.gov/pubmed/35173493
http://dx.doi.org/10.2147/JEP.S341927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842656/
https://www.ncbi.nlm.nih.gov/pubmed/35173493
http://dx.doi.org/10.2147/JEP.S341927

Ejemplares similares